Research paper reviews the efficacy of the first licensed malaria vaccines, RTS,S and R21, highlighting their potential to significantly reduce childhood mortality and discussing future vaccine development strategies.
Moderna touts research progress as it cuts R&D spending by $1.1 billion
Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1 billion, between 2024 and 2027 in a concession